◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › GH

Guardant Health Inc (GH) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-07-24

Guardant Health Inc (GH) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Palo Alto, United States with about 2,490 employees. Its market capitalization is roughly $20 billion. In the fiscal year ended 2025-12-31, GH reported $982M in revenue and ($416M) in net income.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.

Interactive charts & full statements → Open the GH valuation workbench →

GH Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total Revenue	$1.1B	$982M	$739M	$564M	$450M	$374M	$287M	$214M	$91M	$50M	$25M
Gross Profit	$701M	$633M	$449M	$337M	$293M	$251M	$194M	$144M	$47M	$18M	$3M
Gross Margin %	64.9%	64.5%	60.8%	59.7%	65.2%	67.1%	67.7%	67.0%	52.3%	36.6%	12.4%
Operating Income (EBIT)	($448M)	($436M)	($444M)	($565M)	($544M)	($411M)	($255M)	($82M)	($93M)	($77M)	($44M)
Operating Margin %	-41.4%	-44.4%	-60.0%	-100.1%	-121.1%	-110.0%	-88.9%	-38.4%	-102.5%	-153.7%	-173.7%
Net Income	($433M)	($416M)	($436M)	($479M)	($655M)	($406M)	($254M)	($76M)	($85M)	($83M)	($46M)
Net Margin %	-40.1%	-42.4%	-59.1%	-85.0%	-145.6%	-108.6%	-88.5%	-35.3%	-93.8%	-167.0%	-182.7%
EBITDA	($391M)	($374M)	($390M)	($433M)	($615M)	($360M)	($225M)	($55M)	($76M)	($75M)	($39M)
Earnings Per Share (EPS)	$-3.40	$-3.32	$-3.56	$-4.28	$-6.41	$-4.00	$-2.60	$-0.84	$-1.00	$-1.18	$-3.49
Shares Outstanding (M)	131M	125M	123M	112M	102M	101M	98M	91M	85M	71M	13M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GH Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$302M	$281M	$265M	$232M	$203M	$202M	$191M	$177M
Gross Profit	$197M	$182M	$172M	$151M	$129M	$124M	$117M	$105M
Gross Margin %	65.2%	64.6%	64.7%	65.0%	63.3%	61.6%	61.1%	59.1%
Operating Income (EBIT)	($121M)	($121M)	($99M)	($106M)	($111M)	($126M)	($117M)	($101M)
Operating Margin %	-40.2%	-43.0%	-37.3%	-45.9%	-54.6%	-62.4%	-61.3%	-56.8%
Net Income	($112M)	($128M)	($93M)	($100M)	($95M)	($111M)	($108M)	($103M)
Net Margin %	-37.1%	-45.7%	-35.0%	-43.0%	-46.8%	-55.0%	-56.3%	-57.9%
EBITDA	($101M)	($119M)	($82M)	($89M)	($84M)	($99M)	($96M)	($91M)
Earnings Per Share (EPS)	$-0.85	$-1.00	$-0.74	$-0.80	$-0.77	$-0.90	$-0.88	$-0.84
Shares Outstanding (M)	131M	129M	125M	124M	124M	124M	123M	122M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GH Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash from Operations (CFO)	($175M)	($185M)	($240M)	($325M)	($309M)	($209M)	($104M)	($47M)	($72M)	($72M)	($37M)
Capital Expenditures (CapEx)	$49M	$48M	$35M	$20M	$77M	$75M	$54M	$21M	$20M	$9M	$2M
Free Cash Flow (FCF)	($225M)	($233M)	($275M)	($345M)	($387M)	($284M)	($158M)	($68M)	($92M)	($81M)	($38M)
FCF Margin %	-20.8%	-23.7%	-37.2%	-61.3%	-86.1%	-76.0%	-55.1%	-31.9%	-101.9%	-162.9%	-152.4%
Dividends Paid	—	—	—	—	—	$18M	$7M	—	$3M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GH Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	($66M)	($14M)	($35M)	($60M)	($63M)	($65M)	($51M)	($94M)
Capital Expenditures (CapEx)	$6M	$28M	$10M	$6M	$4M	$19M	$4M	$5M
Free Cash Flow (FCF)	($71M)	($42M)	($46M)	($66M)	($67M)	($83M)	($55M)	($99M)
FCF Margin %	-23.6%	-14.9%	-17.3%	-28.4%	-33.0%	-41.3%	-28.9%	-55.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GH Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total Assets	$1.9B	$2.0B	$1.5B	$1.8B	$1.6B	$2.2B	$2.3B	$963M	$587M	$343M	$117M
Cash & Cash Equivalents	$989M	$378M	$526M	$1.1B	$142M	$492M	$833M	$143M	$141M	$72M	$34M
Total Liabilities	$2.1B	$2.1B	$1.6B	$1.6B	$1.6B	$1.6B	$916M	$115M	$62M	$34M	$37M
Total Debt (Short + Long-Term)	$1.5B	$1.5B	$1.2B	$1.2B	$1.2B	$1.1B	$813M	$7M	$0M	$1M	$17M
Total Shareholders' Equity	($181M)	($99M)	($140M)	$159M	$60M	$645M	$1.3B	$798M	$483M	$309M	$80M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GH viewer.

Other Companies in DIAGNOSTICS & RESEARCH

NTRA · Natera Inc — $38 billion
ILMN · Illumina Inc — $29 billion
MEDP · Medpace Holdings Inc — $15 billion
ICLR · ICON PLC — $13 billion

← GGT All stocks GHC →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.